Genmab A/S annual diluted eps
Diluted EPSBasic EPS
2022
2023
2024
2025
Genmab A/S EPS History: Annual & Quarterly (GMAB)
Genmab A/S's diluted EPS was $15.37 for fiscal 2025.
View full Genmab A/S company overviewGenmab A/S annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.37 | $15.50 | -$2.16 | −12.32% |
| 2024 | 2024-12-31 | $17.53 | $17.66 | $7.95 | +82.99% |
| 2023 | 2023-12-31 | $9.58 | $9.67 | $8.38 | +695.71% |
| 2022 | 2022-12-31 | $1.20 | $1.22 | — | — |
Genmab A/S quarterly diluted eps
Diluted EPSBasic EPS
Q2.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.49 | $0.49 | -$4.93 | −90.94% |
| Q1 2026 | 2026-03-31 | $0.08 | $0.08 | -$0.22 | −72.79% |
| Q3 2025 | 2025-09-30 | $0.65 | $0.65 | — | — |
| Q2 2025 | 2025-06-30 | $5.42 | $5.44 | $2.29 | +73.16% |
| Q1 2025 | 2025-03-31 | $0.31 | $0.31 | — | — |
| Q2 2024 | 2024-06-30 | $3.13 | $3.15 | — | — |
Genmab A/S diluted eps trends
Between the periods ended 2022-12-31 and 2025-12-31, Genmab A/S's diluted eps increased from $1.20 to $15.37, a change of $14.17. The latest reported quarter, Q2 2026, shows $0.49.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genmab A/S source filings ↗Community posts
Genmab reports mature survival data for petosemtamab in head and neck cancer
Genmab ($GMAB) reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study of previously untreated, recurrent or metastatic PD-L1-positive head and neck cancer. Among 43 patients evaluable for eff ...
Genmab and Incyte agree colorectal-cancer combination trial
Genmab ($GMAB) and Incyte ($INCY) agreed to test a three-part treatment approach in previously untreated metastatic colorectal cancer carrying a KRAS G12D mutation. The planned Phase 1/2 study combines Genmab’s petosemtamab, an antibody tar ...
